下游加工

{"title":"下游加工","authors":"","doi":"10.1142/9789811224294_0007","DOIUrl":null,"url":null,"abstract":"The fermentation processes that are used by biopharmaceutical manufacturers have shown to lead to increasing quantities of therapeutic proteins. However, this increase in turn leads to capacity bottlenecks in the subsequent purification process (known as downstream processing) and is associated with high costs. Downstream processing comprises up to 80 per cent of the entire production costs. Producers are increasingly recognising the present need for improvement and have shifted their focus from improving the production process (upstream) to improving the downstream process.","PeriodicalId":131220,"journal":{"name":"Macroalgal Biorefineries for the Blue Economy","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Downstream Processing\",\"authors\":\"\",\"doi\":\"10.1142/9789811224294_0007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The fermentation processes that are used by biopharmaceutical manufacturers have shown to lead to increasing quantities of therapeutic proteins. However, this increase in turn leads to capacity bottlenecks in the subsequent purification process (known as downstream processing) and is associated with high costs. Downstream processing comprises up to 80 per cent of the entire production costs. Producers are increasingly recognising the present need for improvement and have shifted their focus from improving the production process (upstream) to improving the downstream process.\",\"PeriodicalId\":131220,\"journal\":{\"name\":\"Macroalgal Biorefineries for the Blue Economy\",\"volume\":\"19 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-11-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Macroalgal Biorefineries for the Blue Economy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1142/9789811224294_0007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Macroalgal Biorefineries for the Blue Economy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1142/9789811224294_0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

生物制药制造商使用的发酵过程已被证明可以增加治疗性蛋白质的数量。然而,这种增加反过来导致后续净化过程(称为下游处理)中的容量瓶颈,并与高成本相关。下游加工占整个生产成本的80%。生产商越来越认识到目前需要改进,并将重点从改善生产过程(上游)转移到改善下游过程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Downstream Processing
The fermentation processes that are used by biopharmaceutical manufacturers have shown to lead to increasing quantities of therapeutic proteins. However, this increase in turn leads to capacity bottlenecks in the subsequent purification process (known as downstream processing) and is associated with high costs. Downstream processing comprises up to 80 per cent of the entire production costs. Producers are increasingly recognising the present need for improvement and have shifted their focus from improving the production process (upstream) to improving the downstream process.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信